Background
==========

Alcohol-induced osteonecrosis of the femoral head (alcohol-induced ONFH) caused by excessive and chronic alcohol consumption is an intractable orthopedic disease that is characterized by the progressive collapse of the femur head and loss of hip joint function. Although there are a variety of clinical treatments, the prevalence of alcohol-induced ONFH and resulting disability in the Chinese population continues to increase, particularly among young men. Data demonstrate that 30.7% of ONFH cases in China are alcohol induced \[[@b1-medscimonit-25-3750]\]. For these reasons, identifying risk factors and taking primary prevention measures are necessary to prevent alcohol-induced ONFH.

Recent research into the molecular biology and genetic underpinnings of alcohol-induced ONFH has provided new information about gene polymorphisms, which has opened up novel avenues of research to uncover the risk factors of this condition \[[@b2-medscimonit-25-3750]\]. In the past few years, genome-wide association studies (GWAS) have identified several susceptibility genes such as *APOA1*, *PAI-1*, *SREBF1*, *VEGF MTHFR*, and*TFPI* that are associated with ONFH \[[@b3-medscimonit-25-3750]--[@b8-medscimonit-25-3750]\]. Chondrocytes from a femoral head with osteonecrosis lose their phenotype during ONFH, revealed by reducing of extracellular matrix production in glycosaminoglycan (GAG) and type 2 collagen excretion \[[@b9-medscimonit-25-3750]\]. In addition, our previous studies demonstrated that *NOS3*, *ABCB, IL23R*, *APOA1*, *APOB*, *TIMP2*, *MMP2*, *MMP3*, and *MMP8* single-nucleotide polymorphisms were related to the risk of alcohol-induced ONFH and clinical outcomes or other clinical characteristics in the Chinese population \[[@b10-medscimonit-25-3750]--[@b13-medscimonit-25-3750]\]. Although multiple gene variants have been proposed as risk factors for alcohol-induced ONFH, the molecular etiology and pathogenesis have remained indistinct.

The *matrix metalloproteinase-20 (MMP20)* gene is located in an *MMP* cluster with 7 other *MMPs* at chromosomal location 11q22.3. *MMP20*, which has been well established as an essential participant in amelogenesis, is expressed in ameloblasts and odontoblasts during dental enamel development and is responsible for cleaving and removing most of the protein components of the extracellular enamel matrix such as amelogenin (the most abundant extracellular matrix (ECM) protein in developing enamel) thus facilitating enamel mineralization \[[@b14-medscimonit-25-3750],[@b15-medscimonit-25-3750]\]. *MMP20* is a relatively newly identified member of the *MMP* family and was also named "human enamelysin" because it was originally thought that *MMP20* expression was restricted to enamel. In recent years, the expression of MMP20 has also been reported in other tissues. A study in 2015 confirmed the expression of *MMP20* in the retina and RPE/choroid \[[@b16-medscimonit-25-3750]\]. Kraus et al. \[[@b17-medscimonit-25-3750]\]investigated the expression of *MMP20* in 3 major human tumor entities: colon, breast, and lung tumors. They found that *MMP20* was identified at both the mRNA and the protein level in breast MCF-7, colon HT-29, and lung A549 cell lines. Thus, they concluded that *MMP20* was a potential new candidate for tumor diagnosis or therapy.

In this case-control study, 14 SNPs on the *MMP20* gene were selected to shed light on possible correlations with the occurrence of alcohol-induced ONFH and the clinical phenotypes in a Chinese male population.

Material and Methods
====================

Study participants
------------------

There were 496 males (299 patients with alcohol-induced ONFH and 197 healthy males) among Han Chinese, sequentially enrolled in this study. All of the patients were selected randomly from the Zhengzhou Traditional Chinese Medicine Traumatology Hospital without restriction of disease severity. The patients were diagnosed with ONFH after using plain radiographs in stage II, III, and IV of the Ficat Classification system. Patients with traumatic osteonecrosis and other hip diseases were excluded. Alcohol-induced osteonecrosis was defined by a history of consumption of more than 400 mL of alcohol per week \[[@b18-medscimonit-25-3750]\]. As well, enrolled patients had not received systemic treatment before the blood samples used for the study were collected. Control study participants were genetically irrelevant healthy males who were enrolled from Zhengzhou Medical Center and lived in or near Zhengzhou without hip pain, without lesions found on hip joint plain radiographs, and without relationship to the enrolled patients. Those who had a chronic metabolic disorder or who needed steroid treatment were also excluded from this study.

A normative questionnaire was used to collect personal information. Our research was approved by the ethics committee of Zhengzhou Traditional Chinese Medicine Traumatology Hospital and The Second Affiliated Hospital of Inner Mongolia Medical University (No. YKD2016138). Signed informed consent documents were obtained from all candidates.

SNP selection and genotyping
----------------------------

A total of 14 SNPs were selected from the NCBI dbSNP (*<http://www.ncbi.nlm.nih.gov/snp>*) and the 1000 Genomes Project databases (*<http://www.internationalgenome.org/>*) with minor allele frequencies (MAFs) \>5% in the 1000 Genomes Chinese Han Beijing population. Genomic DNA was extracted from the peripheral blood of the participants using the GoldMag whole blood genomic DNA purification kit (GoldMag Co. Ltd., Xi'an, China). DNA concentration was determined using a NanoDrop 2000C spectrophotometer (Thermo Scientific, Waltham, MA, USA). Primers for amplification process and single base extension reactions were designed using the Assay Design Suite V2.0 (*<https://agenacx.com/online-tools/>*). SNP genotyping was performed by Agena MassARRAY iPLEX (Agena Bioscience, San Diego, CA, USA). Genotyping results were output by Agena Bioscience TYPER version 4.0 software.

Statistical analysis
--------------------

SPSS 19.0 (version 19.0, Chicago, IL, USA) was used to do the statistical analysis. All the *P*-values were 2-sided, and *P*\<0.05 was considered to be statistically significant. The *t-*test were used to compare the age difference of cases and controls. An exact test was used to assess the variation in each SNP genotype frequency from the Hardy-Weinberg equilibrium (HWE) in the control participants before analysis. Differences in SNP genotype and allele distribution between cases and controls were compared by the χ^2^ test/Wald test. Four models including the codominant, dominant, recessive, and log-additive model were used to assess the association between each genotype and the risk of alcohol-induced ONFH. Finally, both the SHEsis software platform (*<http://analysis.bio-x.cn/myAnalysis.php>*) and the Haploview software (version 4.2) were used to estimate the linkage disequilibrium (LD) patterns and construct haplotypes. The risk associated with individual genotypes and allele was calculated as the odds ratio (OR) with their 95% confidence interval (95% CI) based on logistic regression model analysis with an adjustment for age.

Results
=======

Altogether, 299 eligible cases with alcohol-induced ONFH (mean age ±SD: 43.24±13.07) and 197 controls (mean age ±SD: 49.71±8.85) were recruited for our study. All of the individuals were males. The results of *t*-tests showed that the cases and controls were not matched for age (*P*\<0.05), so we adjusted the age factor in the subsequent analysis ([Table 1](#t1-medscimonit-25-3750){ref-type="table"}).

The detailed information about the 14 selected SNPs on the *MMP20* gene including band, alleles, minor allele frequency (MAF), and HWE results. The *P*-values of alleles were calculated by chi-square test. All SNPs did not deviate from HWE (*P*\>0.05). Comparing the differences in MAF distributions between cases and controls, we found that 4 SNPs may significantly correlate with the risk of alcohol-induced ONFH under the allele model (rs10895322G/A, OR=1.422, 95% CI=1.069--1.892, *P*=0.015; rs1784424T/G, OR=1.368, 95% CI=1.059--1.767, *P*=0.016; rs3781788T/C, OR=1.345, 95% CI=1.031--1.755, *P*=0.029; rs1573954C/T, OR=1.328, 95% CI=1.028--1.716, *P*=0.030) ([Table 2](#t2-medscimonit-25-3750){ref-type="table"}).

Subsequently, by unconditional logistic-regression analysis, we further identified the correlation between selected SNPs and alcohol-induced ONFH risk under 4 gene models (codominant, dominant, recessive, and log-additive). Meanwhile, all results were adjusted by age ([Table 3](#t3-medscimonit-25-3750){ref-type="table"}). Rs10895322 and rs1784424 notably increased the risk of alcohol-induced ONFH under all of the gene models, including codominant, dominant, recessive, and log-additive. Rs3781788 also revealed an increased risk under both the dominant and the additive model. Meanwhile, both rs7126560 and rs2292730 revealed an increased risk under the log-additive model, rs1573954 exhibited an increased risk under 2 models (recessive and log-additive), and rs1711399 revealed an increased risk under the recessive model. In addition, rs1711423 showed a negative effect under the recessive and log-additive models, and rs1784418 also showed a decreased risk under both the dominant model and the log-additive model.

Next, we completed the correlation analysis of alleles and genotypes of SNPs with the clinical phenotypes (unilateral or bilateral hip lesions, \>12 months or ≤12 months course, and clinical stages of alcohol-induced ONFH), respectively ([Table 4](#t4-medscimonit-25-3750){ref-type="table"}). Regarding rs10895322, some significant association was found between the G allele and the patients with different clinical phenotypes. In patients who had bilateral hip lesions, \>12 months course, and/or stage II/III alcohol-induced ONFH, the G allele was a risk factor. Likewise, the rs3781788 T allele showed the same results. Among patients who had bilateral hip lesions, \>12 months course, and/or stage III alcohol-induced ONFH, the G allele of rs1784424 showed significantly increased risk, and the G allele of rs1711423 showed significantly decreased risk, relative to controls. In addition, the allele distribution showed a higher frequency of the rs1573954 C allele in the patients with unilateral hip lesions, ≤12 months course, and/or stage II alcohol-induced ONFH. Rs1784418 showed a decreased risk in patients with \>12 months course or/and stage III of alcohol-induced ONFH. Regarding rs7126560 and rs2292730, these 2 SNPs only revealed the increased risk for \>12 months course and stage IV alcohol-induced ONFH, respectively.

Finally, using parameter D', we detected the extent of linkage disequilibrium between SNPs, and then determined the haplotype LD block according to the control group data. We observed that 2 blocks existed strong linkage disequilibria in *MMP20* ([Figure 1](#f1-medscimonit-25-3750){ref-type="fig"}). Block 1 included 8 SNPs: rs1711437, rs10895322, rs1784424, rs3781788, rs1711423, rs17174327, rs1784418, and rs7126560; block 2 includes 2 SNPs: rs1784410 and rs11711399. In block 1, compared with the "TATCGCTG" wild-type, the "CGGTTCCA" haplotype was found to be associated with an increased alcohol-induced ONFH risk after adjustment for age (OR=1.63, 95% CI=1.15--2.30, *P*=0.0058) ([Table 5](#t5-medscimonit-25-3750){ref-type="table"}). However, we did not find any association between alcohol-induced ONFH and the haplotype of block 2.

Discussion
==========

In this study, we have attempted to show the correlation between MMP20 polymorphisms and alcohol-induced ONFH and the different clinical phenotypes in Chinese Han males. Nine susceptibility SNPs in the *MMP20* gene revealed a statistically significant association with the alcohol-induced ONFH occurrence: 2 protective SNPs (rs1711423 and rs1784418) and 7 high-risk SNPs (rs10895322, rs1784424, rs3781788, rs7126560, rs1573954, rs1711399, and rs2292730). Among these SNPs, 8 SNPs showed a statistically significant association with different clinical phenotypes. In particular, the haplotype "CGGTTCCA" in *MMP20* was also founded to be correlated with a 1.63-fold increased risk of alcohol-induced ONFH. As far as we know, this is the first report to reveal the correlation between these *loci* and ONFH susceptibility.

MMPs devastate the cartilaginous extracellular matrix (ECM) production during chondrogenesis \[[@b19-medscimonit-25-3750],[@b20-medscimonit-25-3750]\] and ONFH \[[@b9-medscimonit-25-3750]\]. And ECM, including GAG and collagen type 2, are commodities not only in normal chondrocytes but also in chondrocytic differentiation \[[@b21-medscimonit-25-3750]\]. MMP20 may inhibit the synthesis of ECM of chodrocytes in the femoral heads under osteonecrosis. But studies on these risk *loci* are relatively rare. A recent GWAS reported a susceptibility locus (rs10895322) for 11q-deletion neuroblastoma, and 11q deletion is an inversely correlated prognostic factor in neuroblastoma \[[@b22-medscimonit-25-3750]\]. In 2015, another GWAS identified association between rs10895322 and neovascular lesion size in age-related macular degeneration (AMD), which suggests the possibility of using *MMP20* as a novel target to control the growth of choroidal neovascularization (CNV) after the onset of AMD \[[@b16-medscimonit-25-3750]\]. Similarly, in this study, we found that rs10895322 may be a high-risk factor of alcohol-induced ONFH, implying that the risk attributed to rs10895322 in ONFH and neuroblastoma may be mediated through a comparable angiogenesis process that is regulated by *MMP20*.

In a family-based association study, Jeremias et al. \[[@b23-medscimonit-25-3750]\] concluded that rs1711399 and rs1711423 were associated with the susceptibility to molar-incisor hypomineralization (MIH). Our study showed that rs1711399 played a risk-heightening role in the occurrence of alcohol-induced ONFH, while rs1711423 may be a protective SNP. We hold the opinion that there are genetic differences between the 2 diseases.

In our study, rs1784418 was also a protective SNP concerning the occurrence of alcohol-induced ONFH in both dominant and log-additive genetic models. In 2012, Tannure et al. \[[@b24-medscimonit-25-3750]\] speculated that rs1784418 C\>T may be involved with caries susceptibility in primarily Caucasian patients with poor oral health habits. A similar study by Filho et al. in 2016 explored the association of rs1784418 C\>T and dental caries experience. Their conclusion is that the rs1784418 T allele can potentially be used as a marker for lower caries risk in certain populations \[[@b25-medscimonit-25-3750]\]. The latest report from Brazil by Antunes et al. \[[@b26-medscimonit-25-3750]\] suggested that *MMP20* rs1784418 C\>T may contribute to the occurrence of white spot lesions in the primary dentition. The aforementioned conclusions are consistent with our results; though the function of rs1784418 is unknown, there is a possibility that the variant affects the transcription of *MMP20*. In the study by Han et al. \[[@b27-medscimonit-25-3750]\], they analyzed the correlations between polymorphisms of rs1711437 (G\>A) and kidney transplantation outcomes in 235 transplant recipients. The conclusions suggest that *MMP20* polymorphisms may influence the long-term outcome of kidney allografts. Beyond that, the *MMP20* gene also has been shown to be related to kidney aging by Wheeler et al. \[[@b28-medscimonit-25-3750]\]. They showed that the A allele at rs1711437 was associated with high glomerular filtration rate (GFR). However, our study found no relationship between this locus and alcohol-induced ONFH. The study by Wang et al. \[[@b29-medscimonit-25-3750]\] in 2015 suggested that *MMP20* rs2292730, rs12278250, and rs9787933 might be associated with ovarian cancer risk in a group of 417 ovarian cancer cases and 417 controls. In contrast to this conclusion, a comprehensive meta-analysis by Zhu and Sun \[[@b30-medscimonit-25-3750]\] in 2017 found that these 3 *loci* might not be associated with ovarian cancer risk. Our present study only indicated that rs2292730 is a risk SNP of alcohol-induced ONFH among these 3 SNPs. In the study by Kanna et al. \[[@b31-medscimonit-25-3750]\], genetic polymorphisms of *MMP20* (rs17099008) were significantly associated with Modic changes, which are vertebral endplate signal changes predominantly observed in the lumbar spine. Our study did not include this site. It is necessary to conduct larger-scale, multicenter, and high-quality studies in the future.

Up to now, the other 4 high-risk sites (rs1784424, rs3781788, rs7126560, and rs1573954) have not been described in other diseases. Collectively, our study provides insight into the pathogenesis of alcohol-induced ONFH. Although this study had an adequately sufficient statistical power, some intrinsic limitations may still exist. First, our study did not perform a functional study of these SNPs. To clarify the function of *MMP20* in alcohol-induced ONFH, SNPs functional study is essential. Second, the sample capacity was relatively small; a larger sample capacity will be more persuasive. Finally, participants' ethnicity was limited to the Han Chinese population. Hence, the associations identified in this study should be confirmed in further studies with other ethnic groups.

Conclusions
===========

We demonstrated in this study that *MMP20* polymorphisms can play both risk-heightening and risk-mitigating roles and that *MMP20* may serve as a marker to predict the occurrence of alcohol-induced ONFH. These findings were in agreement with the multifactorial etiology of alcohol-induced ONFH. However, because of the lack of functional studies and the fact that most intronic SNPs are nonfunctional, these results more likely suggest that other coding SNP(s) tagged by these positive SNPs might be causal to alcohol-induced ONFH*.*
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###### 

Characteristics of the male individuals in controls and alcohol-induced ONFH patients.

  Variables         Cases (n=299)   Controls (n=197)   *P* value
  ----------------- --------------- ------------------ ----------------------------------------------------------------
  Age, years                                           
   Mean ±SD         43.24±13.07     49.76±8.83         *P*\<0.001[\*](#tfn2-medscimonit-25-3750){ref-type="table-fn"}
   ≤50              215 (71.9)      113 (57.4)         
   \>50             84 (28.1)       84 (42.6)          
  Clinical stages                                      
   Stage II         74 (24.7)                          
   Stage III        121 (40.5)                         
   Stage IV         104 (34.8)                         
  Hip lesions                                          
   Unilateral       70 (23.4)                          
   Bilateral        229 (76.6)                         
  Course, months                                       
   \>12             151 (50.5)                         
   ≤12              148 (49.5)                         

*P*\<0.05 indicates statistical significance.

Independent samples *t*-test.

###### 

Basic information of candidate SNPs in this study.

  SNP ID       Gene    Band      Alleles A/B   MAF     HWE *P*[a](#tfn5-medscimonit-25-3750){ref-type="table-fn"} value   ORs     95% CI     *P*[b](#tfn6-medscimonit-25-3750){ref-type="table-fn"} value              
  ------------ ------- --------- ------------- ------- ------------------------------------------------------------------ ------- ---------- -------------------------------------------------------------- ---------- ---------------------------------------------------------------
  rs2292730    MMP20   11q22.2   A/G           0.296   0.254                                                              0.192   1.24       0.93                                                           1.64       0.147
  rs1784410    MMP20   11q22.2   C/A           0.401   0.424                                                              1.000   0.91       0.70                                                           1.18       0.474
  rs1711399    MMP20   11q22.2   G/T           0.462   0.418                                                              0.559   1.19       0.92                                                           1.54       0.181
  rs1711437    MMP20   11q22.2   T/C           0.385   0.413                                                              1.000   0.89       0.69                                                           1.16       0.379
  rs1711433    MMP20   11q22.2   C/T           0.010   0.005                                                              1.000   1.99       0.40                                                           9.89       0.623
  rs10895322   MMP20   11q22.2   G/A           0.326   0.254                                                              0.851   **1.42**   **1.07**                                                       **1.89**   **0.015**[\*](#tfn4-medscimonit-25-3750){ref-type="table-fn"}
  rs1784424    MMP20   11q22.2   T/G           0.575   0.497                                                              0.775   **1.37**   **1.06**                                                       **1.77**   **0.016**[\*](#tfn4-medscimonit-25-3750){ref-type="table-fn"}
  rs3781788    MMP20   11q22.2   T/C           0.403   0.334                                                              0.521   **1.35**   **1.03**                                                       **1.76**   **0.029**[\*](#tfn4-medscimonit-25-3750){ref-type="table-fn"}
  rs1711423    MMP20   11q22.2   G/T           0.425   0.487                                                              1.000   0.78       0.60                                                           1.00       0.053
  rs17174327   MMP20   11q22.2   T/C           0.062   0.087                                                              0.370   0.69       0.43                                                           1.13       0.138
  rs1784418    MMP20   11q22.2   T/C           0.428   0.487                                                              0.670   0.79       0.61                                                           1.02       0.067
  rs7126560    MMP20   11q22.2   A/G           0.404   0.343                                                              1.000   1.30       0.10                                                           1.69       0.053
  rs2245803    MMP20   11q22.2   G/A           0.002   0.005                                                              1.000   0.33       0.03                                                           3.64       0.717
  rs1573954    MMP20   11q22.2   C/T           0.555   0.485                                                              0.317   **1.33**   **1.03**                                                       **1.72**   **0.030**[\*](#tfn4-medscimonit-25-3750){ref-type="table-fn"}

A -- minor alleles; B -- major alleles;

*P*\<0.05 indicates statistical significance;

*P* was calculated by exact test;

*P* was calculated by Pearson chi-squared test.

Bold values indicate a significant difference.

###### 

Genotypic model analysis of relationship between SNPs and alcohol-induced ONFH risk adjusted for age.

  SNP ID       Model          Genotype   Control       Case          OR (95% CI)             *P*[a](#tfn9-medscimonit-25-3750){ref-type="table-fn"}-value     AIC     BIC
  ------------ -------------- ---------- ------------- ------------- ----------------------- ---------------------------------------------------------------- ------- -------
  rs10895322   Codominant     AA         109 (55.9%)   136 (46%)     1                       **0.018**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    625.9   642.6
                              GA         73 (37.4%)    127 (42.9%)   1.44 (0.97--2.14)                                                                                
                              GG         13 (6.7%)     33 (11.2%)    **2.47 (1.21--5.04)**                                                                            
               Dominant       AA         109 (55.9%)   136 (46%)     1                       **0.016**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    626.1   638.7
                              GA-GG      86 (44.1%)    160 (54%)     **1.58 (1.09--2.31)**                                                                            
               Recessive      AA-GA      182 (93.3%)   263 (88.8%)   1                       **0.029**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    627.1   639.7
                              GG         13 (6.7%)     33 (11.2%)    **2.10 (1.05--4.19)**                                                                            
               Log-additive   --         --            --            **1.51 (1.13--2.03)**   **0.0051**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}   624     636.6
  rs1784424    Codominant     TT         48 (24.5%)    52 (17.4%)    1                       **0.018**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    629.8   646.6
                              GT         101 (51.5%)   150 (50.2%)   1.43 (0.88--2.33)                                                                                
                              GG         47 (24%)      97 (32.4%)    **2.18 (1.26--3.77)**                                                                            
               Dominant       TT         48 (24.5%)    52 (17.4%)    **1**                   **0.032**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    631.2   643.8
                              GT-GG      148 (75.5%)   247 (82.6%)   **1.66 (1.05--2.63)**                                                                            
               Recessive      TT-GT      149 (76%)     202 (67.6%)   **1**                   **0.014**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    629.9   642.5
                              GG         47 (24%)      97 (32.4%)    **1.69 (1.10--2.58)**                                                                            
               Log-additive   --         --            --            **1.48 (1.13--1.94)**   **0.0046**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}   627.8   640.4
  rs3781788    Codominant     CC         89 (45.4%)    104 (34.8%)   1                       0.072                                                            632.6   649.4
                              CT         83 (42.4%)    149 (49.8%)   1.53 (1.02--2.29)                                                                                
                              TT         24 (12.2%)    46 (15.4%)    1.66 (0.92--2.99)                                                                                
               Dominant       CC         89 (45.4%)    104 (34.8%)   1                       **0.023**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    630.7   643.3
                              CT-TT      107 (54.6%)   195 (65.2%)   **1.56 (1.06--2.28)**                                                                            
               Recessive      CC-CT      172 (87.8%)   253 (84.6%)   1                       0.310                                                            634.8   647.4
                              TT         24 (12.2%)    46 (15.4%)    1.33 (0.77--2.29)                                                                                
               Log-additive   --         --            --            **1.35 (1.02--1.78)**   **0.032**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    631.3   643.9
  rs1711423    Codominant     TT         51 (26%)      97 (32.4%)    1                       0.052                                                            631.9   648.7
                              GT         99 (50.5%)    150 (50.2%)   0.74 (0.48--1.16)                                                                                
                              GG         46 (23.5%)    52 (17.4%)    0.51 (0.30--0.88)                                                                                
               Dominant       TT         51 (26%)      97 (32.4%)    1                       0.057                                                            632.2   644.8
                              GT-GG      145 (74%)     202 (67.6%)   0.67 (0.44--1.02)                                                                                
               Recessive      TT-GT      150 (76.5%)   247 (82.6%)   1                       **0.042**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    631.7   644.3
                              GG         46 (23.5%)    52 (17.4%)    **0.62 (0.39--0.98)**                                                                            
               Log-additive   --         --            --            **0.72 (0.55--0.94)**   **0.016**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    630     642.6
  rs1784418    Codominant     CC         50 (25.4%)    96 (32.1%)    1                       0.066                                                            633.5   650.3
                              CT         102 (51.8%)   150 (50.2%)   0.71 (0.45--1.10)                                                                                
                              TT         45 (22.8%)    53 (17.7%)    0.53 (0.31--0.91)                                                                                
               Dominant       CC         50 (25.4%)    96 (32.1%)    1                       **0.043**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    632.8   645.4
                              CT-TT      147 (74.6%)   203 (67.9%)   **0.65 (0.43--0.99)**                                                                            
               Recessive      CC-CT      152 (77.2%)   246 (82.3%)   1                       0.082                                                            633.9   646.5
                              TT         45 (22.8%)    53 (17.7%)    0.66 (0.41--1.05)                                                                                
               Log-additive   --         --            --            **0.73 (0.55--0.95)**   **0.020**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    631.5   644.1
                                                                                                                                                                      
  rs7126560    Codominant     GG         85 (43.1%)    104 (35.1%)   1                       0.130                                                            633     649.8
                              AG         89 (45.2%)    145 (49%)     1.35 (0.90--2.02)                                                                                
                              AA         23 (11.7%)    47 (15.9%)    1.73 (0.95--3.13)                                                                                
               Dominant       GG         85 (43.1%)    104 (35.1%)   1                       0.068                                                            631.7   644.3
                              AG-AA      112 (56.9%)   192 (64.9%)   1.43 (0.97--2.09)                                                                                
               Recessive      GG-AG      174 (88.3%)   249 (84.1%)   1                       0.170                                                            633.1   645.7
                              AA         23 (11.7%)    47 (15.9%)    1.47 (0.84--2.54)                                                                                
               Log-additive   --         --            --            1.32 (1.00--1.75)       **0.045**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    631     643.6
  rs1573954    Codominant     TT         48 (24.6%)    59 (19.8%)    1                       0.050                                                            628.4   645.2
                              TC         105 (53.9%)   147 (49.3%)   1.31 (0.81--2.11)                                                                                
                              CC         42 (21.5%)    92 (30.9%)    1.95 (1.13--3.37)                                                                                
               Dominant       TT         48 (24.6%)    59 (19.8%)    1                       0.081                                                            629.4   642
                              TC-CC      147 (75.4%)   239 (80.2%)   1.50 (0.95--2.36)                                                                                
               Recessive      TT-TC      153 (78.5%)   206 (69.1%)   1                       **0.030**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    627.7   640.3
                              CC         42 (21.5%)    92 (30.9%)    **1.61 (1.04--2.49)**                                                                            
               Log-additive   --         --            --            **1.40 (1.06--1.84)**   **0.015**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    626.5   639.1
  rs1711399    Codominant     TT         64 (32.6%)    90 (30.1%)    1                       0.071                                                            631.9   648.7
                              GT         100 (51%)     142 (47.5%)   1.02 (0.67--1.57)                                                                                
                              GG         32 (16.3%)    67 (22.4%)    1.78 (1.02--3.10)                                                                                
               Dominant       TT         64 (32.6%)    90 (30.1%)    1                       0.390                                                            634.4   647.1
                              GT-GG      132 (67.3%)   209 (69.9%)   1.19 (0.80--1.79)                                                                                
               Recessive      TT-GT      164 (83.7%)   232 (77.6%)   1                       **0.021**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    629.9   642.5
                              GG         32 (16.3%)    67 (22.4%)    **1.75 (1.08--2.85)**                                                                            
               Log-additive   --         --            --            1.29 (0.99--1.68)       0.063                                                            631.7   644.3
  rs2292730    Codominant     GG         106 (53.8%)   140 (46.8%)   1                       0.120                                                            634.7   651.5
                              GA         82 (41.6%)    141 (47.2%)   1.39 (0.94--2.04)                                                                                
                              AA         9 (4.6%)      18 (6%)       1.94 (0.81--4.66)                                                                                
               Dominant       GG         106 (53.8%)   140 (46.8%)   1                       0.058                                                            633.3   645.9
                              GA-AA      91 (46.2%)    159 (53.2%)   1.44 (0.99--2.09)                                                                                
               Recessive      GG-GA      188 (95.4%)   281 (94%)     1                       0.240                                                            635.5   648.1
                              AA         9 (4.6%)      18 (6%)       1.66 (0.71--3.90)                                                                                
               Log-additive   --         --            --            **1.39 (1.01--1.91)**   **0.041**[\*](#tfn8-medscimonit-25-3750){ref-type="table-fn"}    632.7   645.3

*P***\<**0.05 indicates statistical significance.

*P* values were calculated by Wald test by unconditional logistic regression adjusted for age.

Bold values indicate a significant difference.

###### 

Stratification analysis for association of *MMP20* gene polymorphism with the clinical phenotypes of alcohol-induced ONFH.

  SNPs             Genotype (%)   Allele (%)                                                                                                                                                                                                   
  ---------------- -------------- ------------ ----------- ---------------------------------------------------------------- ------------ ------------ ---------------------------------------------------------------- ---------- ------------ ----------
  **rs2292730**    **GG**         **GA**       **AA**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **G**        **A**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         106 (53.8)     82 (41.6)    9 (4.60)                                                                     294 (74.6)   100 (25.4)                                                                                            
  Unilateral       32 (45.7)      32 (45.7)    6 (8.60)    0.320                                                            96 (68.6)    44 (31.4)    0.166                                                            1.35       0.88         2.06
  Bilateral        108 (47.2)     109 (47.6)   12 (5.20)   0.190                                                            325 (71.0)   133 (29.0)   0.232                                                            1.20       0.89         1.63
  Stage II         32 (43.2)      39 (52.7)    3 (4.00)    0.320                                                            103 (69.6)   45 (30.4)    0.239                                                            1.28       0.85         1.95
  Stage III        66 (54.5)      51 (42.1)    4 (3.30)    0.780                                                            183 (75.6)   59 (24.4)    0.948                                                            0.65       1.37         0.78
  Stage IV         42 (40.4)      51 (49.0)    11 (10.6)   **0.023**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   135 (64.9)   73 (35.1)    **0.012**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.59**   **1.10**     **2.29**
  \>12 months      76 (50.3)      67 (44.4)    8 (5.30)    0.710                                                            219 (72.5)   83 (27.5)    0.532                                                            1.11       0.79         1.56
  ≤12 months       64 (43.2)      74 (50.0)    10 (6.80)   **0.043**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   202 (68.2)   94 (31.8)    0.065                                                            1.37       0.98         1.91
  **rs1784410**    **AA**         **CA**       **CC**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **A**        **C**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         65 (33.0)      97 (49.2)    35 (17.8)                                                                    227 (57.6)   167 (42.4)                                                                                            
  Unilateral       25 (35.7)      30 (42.9)    15 (21.4)   0.710                                                            80 (57.1)    60 (42.9)    0.923                                                            1.02       0.69         1.51
  Bilateral        84 (36.8)      109 (47.8)   35 (15.3)   0.310                                                            277 (60.7)   179 (39.3)   0.354                                                            0.88       0.67         1.16
  Stage II         25 (34.2)      32 (43.8)    16 (21.9)   0.880                                                            82 (56.2)    64 (43.8)    0.762                                                            1.06       0.72         1.56
  Stage III        45 (37.2)      65 (53.7)    11 (9.1)    **0.012**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   155 (64.0)   87 (36.0)    0.108                                                            0.76       0.55         1.06
  Stage IV         39 (37.5)      42 (40.4)    23 (22.1)   0.350                                                            120 (57.7)   88 (42.3)    0.985                                                            1.00       0.71         1.40
  \>12 months      57 (38.0)      71 (47.3)    22 (14.7)   0.520                                                            185 (61.7)   115 (38.3)   0.282                                                            0.84       0.62         1.15
  ≤12 months       52 (35.1)      68 (46.0)    28 (18.9)   0.570                                                            172 (58.1)   124 (41.9)   0.897                                                            0.98       0.72         1.33
  **rs1711399**    **TT**         **GT**       **GG**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **T**        **G**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         64 (32.6)      100 (51)     32 (16.3)                                                                    228 (58.2)   164 (41.8)                                                                                            
  Unilateral       22 (31.4)      31 (44.3)    17 (24.3)   0.230                                                            75 (53.6)    65 (46.4)    0.346                                                            1.20       0.82         1.78
  Bilateral        68 (29.7)      111 (48.5)   50 (21.8)   0.120                                                            247 (53.9)   211 (46.1)   0.215                                                            1.19       0.90         1.56
  Stage II         19 (25.7)      41 (55.4)    14 (18.9)   0.450                                                            79 (53.4)    69 (46.6)    0.317                                                            1.21       0.83         1.78
  Stage III        32 (26.4)      60 (49.6)    29 (24.0)   **0.013**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   124 (51.2)   118 (48.8)   0.088                                                            1.32       0.96         1.83
  Stage IV         39 (37.5)      41 (39.4)    24 (23.1)   0.120                                                            119 (57.2)   89 (42.8)    0.822                                                            1.04       0.74         1.46
  \>12 months      43 (28.5)      70 (46.4)    38 (25.2)   0.088                                                            156 (51.7)   146 (48.3)   0.087                                                            1.30       0.96         1.76
  ≤12 months       47 (31.8)      72 (48.6)    29 (19.6)   0.280                                                            166 (56.1)   130 (43.9)   0.585                                                            1.09       0.80         1.48
  **rs1711437**    **CC**         **TC**       **TT**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **C**        **T**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         67 (34.4)      95 (48.7)    33 (16.9)                                                                    229 (58.7)   161 (41.3)                                                                                            
  Unilateral       26 (37.1)      30 (42.9)    14 (20.0)   0.800                                                            82 (58.6)    58 (41.4)    0.976                                                            1.01       0.68         1.49
  Bilateral        87 (38.7)      107 (47.6)   31 (13.8)   0.230                                                            281 (62.4)   169 (37.6)   0.270                                                            0.86       0.65         1.13
  Stage II         28 (38.4)      33 (45.2)    12 (16.4)   0.540                                                            89 (61.0)    57 (39.0)    0.638                                                            0.91       0.62         1.34
  Stage III        46 (38.0)      65 (53.7)    10 (8.30)   **0.005**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   157 (64.9)   85 (35.1)    0.123                                                            0.77       0.55         1.07
  Stage IV         39 (38.6)      39 (38.6)    23 (22.8)   0.240                                                            117 (57.9)   85 (42.1)    0.852                                                            1.03       0.73         1.46
  \>12 months      59 (39.6)      69 (46.3)    21 (14.1)   0.480                                                            187 (62.8)   111 (37.2)   0.284                                                            0.84       0.62         1.15
  ≤12 months       54 (37.0)      68 (46.6)    24 (16.4)   0.440                                                            176 (60.3)   116 (39.7)   0.682                                                            0.94       0.69         1.28
  **rs10895322**   **AA**         **GA**       **GG**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **A**        **G**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95%CI**    
  Controls         109 (55.9)     73 (37.4)    13 (6.70)                                                                    291 (74.6)   99 (25.4)                                                                                             
  Unilateral       34 (49.3)      26 (37.7)    9 (13.0)    0.110                                                            94 (68.1)    44 (31.9)    0.140                                                            1.38       0.90         2.10
  Bilateral        102 (44.9)     101 (44.5)   24 (10.6)   **0.022**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   305 (67.2)   149 (32.8)   **0.018**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.44**   **1.06**     **1.94**
  Stage II         30 (41.1)      36 (49.3)    7 (9.60)    **0.049**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   96 (65.8)    50 (34.2)    **0.041**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.53**   **1.02**     **2.31**
  Stage III        54 (45.0)      51 (42.5)    15 (12.5)   **0.007**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   159 (66.3)   81 (33.8)    **0.024**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.50**   **1.05**     **2.13**
  Stage IV         52 (50.5)      40 (38.8)    11 (10.7)   0.410                                                            144 (69.9)   62 (30.1)    0.218                                                            1.27       0.87         1.84
  \>12 months      63 (41.7)      69 (45.7)    19 (12.6)   **0.016**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   195 (64.6)   107 (35.4)   **0.004**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.61**   **1.16**     **2.24**
  ≤12 months       73 (50.3)      58 (40.0)    14 (9.70)   0.092                                                            204 (70.3)   86 (29.7)    0.216                                                            1.24       0.88         1.74
  **rs1784424**    **TT**         **GT**       **GG**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **T**        **G**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         48 (24.5)      101 (51.5)   47 (24.0)                                                                    197 (50.3)   195 (49.7)                                                                                            
  Unilateral       15 (21.7)      33 (47.8)    21 (30.4)   0.490                                                            63 (45.7)    75 (54.3)    0.140                                                            1.38       0.90         2.10
  Bilateral        36 (15.7)      117 (51.1)   76 (33.2)   **0.006**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   189 (41.3)   269 (58.7)   **0.009**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.44**   **1.10**     **1.89**
  Stage II         13 (17.6)      35 (47.3)    26 (35.1)   **0.035**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   61 (41.2)    87 (58.8)    0.061                                                            1.44       0.98         2.11
  Stage III        14 (11.7)      65 (54.2)    41 (34.2)   **0.001**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   93 (38.8)    147 (61.3)   **0.005**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.60**   **1.15**     **2.21**
  Stage IV         24 (23.1)      50 (48.1)    30 (28.9)   0.650                                                            98 (47.1)    110 (52.9)   0.464                                                            1.13       0.81         1.59
  \>12 months      25 (16.6)      73 (48.3)    53 (35.1)   **0.031**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   123 (40.7)   179 (59.3)   **0.013**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.47**   **1.09**     **1.99**
  ≤12 months       26 (17.7)      77 (52.4)    44 (29.9)   0.060                                                            129 (43.9)   165 (56.1)   0.098                                                            1.29       0.95         1.75
  **rs3781788**    **CC**         **CT**       **TT**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **C**        **T**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         89 (45.4)      83 (42.4)    24 (12.2)                                                                    261 (66.6)   131 (33.4)                                                                                            
  Unilateral       27 (39.1)      29 (42.0)    13 (18.8)   0.340                                                            83 (60.1)    55 (39.9)    0.173                                                            1.32       0.88         1.97
  Bilateral        76 (33.2)      120 (52.4)   33 (14.4)   **0.028**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   272 (59.4)   186 (40.6)   **0.031**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.36**   **1.03**     **1.80**
  Stage II         23 (31.1)      37 (50.0)    14 (18.9)   0.061                                                            83 (56.1)    65 (43.9)    **0.024**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.56**   **1.06**     **2.30**
  Stage III        36 (30.0)      68 (56.7)    16 (13.3)   **0.023**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   140 (58.3)   100 (41.7)   **0.037**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.42**   **1.02**     **1.98**
  Stage IV         44 (42.3)      44 (42.3)    16 (15.4)   0.720                                                            132 (63.5)   76 (36.5)    0.444                                                            1.15       0.81         1.63
  \>12 months      50 (33.1)      74 (49.0)    27 (17.9)   **0.048**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   174 (57.6)   128 (42.4)   **0.015**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.47**   **1.07**     **2.00**
  ≤12 months       53 (36.0)      75 (51.0)    19 (12.9)   0.310                                                            181 (61.6)   113 (38.4)   0.174                                                            1.24       0.91         1.70
  **rs1711423**    **TT**         **GT**       **GG**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **T**        **G**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         51 (26.0)      99 (50.5)    46 (23.5)                                                                    201 (51.3)   191 (48.7)                                                                                            
  Unilateral       23 (32.9)      31 (44.3)    16 (22.9)   0.560                                                            77 (55.0)    63 (45.0)    0.449                                                            0.86       0.58         1.27
  Bilateral        74 (32.3)      119 (52.0)   36 (15.7)   **0.021**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   267 (58.3)   191 (41.7)   **0.040**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **0.75**   **0.57**     **0.99**
  Stage II         25 (33.8)      34 (46.0)    15 (20.3)   0.140                                                            84 (56.8)    64 (43.2)    0.255                                                            0.80       0.55         1.17
  Stage III        42 (34.7)      65 (53.7)    14 (11.6)   **0.001**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   149 (61.6)   93 (38.4)    **0.011**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **0.66**   **0.47**     **0.91**
  Stage IV         30 (28.9)      51 (49.0)    23 (22.1)   0.860                                                            111 (53.4)   97 (46.6)    0.626                                                            0.92       0.66         1.29
  \>12 months      52 (34.4)      75 (49.7)    24 (15.9)   0.081                                                            179 (59.3)   123 (40.7)   **0.036**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **0.72**   **0.53**     **0.98**
  ≤12 months       45 (30.4)      75 (50.7)    28 (18.9)   0.120                                                            165 (55.7)   131 (44.3)   0.245                                                            0.84       0.62         1.13
  **rs1784418**    **CC**         **CT**       **TT**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **C**        **T**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         50 (25.4)      102 (51.8)   45 (22.8)                                                                    202 (51.3)   192 (48.7)                                                                                            
  Unilateral       25 (35.7)      29 (41.4)    16 (22.9)   0.280                                                            79 (56.4)    61 (43.6)    0.294                                                            0.81       0.55         1.20
  Bilateral        71 (31.0)      121 (52.8)   37 (16.2)   **0.044**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   263 (57.4)   195 (42.6)   0.072                                                            0.78       0.60         1.02
  Stage II         25 (33.8)      34 (46.0)    15 (20.3)   0.150                                                            84 (56.8)    64 (43.2)    0.254                                                            0.80       0.55         1.17
  Stage III        40 (33.1)      67 (55.4)    14 (11.6)   **0.001**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   147 (60.7)   95 (39.3)    **0.020**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **0.68**   **0.49**     **0.94**
  Stage IV         31 (29.8)      49 (47.1)    24 (23.1)   0.700                                                            111 (53.4)   97 (46.6)    0.624                                                            0.92       0.66         1.29
  \>12 months      52 (34.4)      74 (49.0)    25 (16.6)   0.096                                                            178 (58.9)   124 (41.1)   **0.044**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **0.73**   **0.54**     **0.99**
  ≤12 months       44 (29.7)      76 (51.4)    28 (18.9)   0.140                                                            164 (55.4)   132 (44.6)   0.281                                                            0.85       0.63         1.15
  **rs7126560**    **GG**         **AG**       **AA**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **G**        **A**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         85 (43.1)      89 (45.2)    23 (11.7)                                                                    259 (65.7)   135 (34.3)                                                                                            
  Unilateral       27 (38.6)      29 (41.4)    14 (20.0)   0.220                                                            83 (59.3)    57 (40.7)    0.172                                                            1.32       0.89         1.96
  Bilateral        77 (34.1)      116 (51.3)   33 (14.6)   0.100                                                            270 (59.7)   182 (40.3)   0.072                                                            1.29       0.98         1.71
  Stage II         23 (31.1)      38 (51.4)    13 (17.6)   0.089                                                            84 (56.8)    64 (43.2)    0.053                                                            1.46       0.99         2.15
  Stage III        37 (30.6)      67 (55.4)    17 (14.1)   0.051                                                            141 (58.3)   101 (41.7)   0.058                                                            1.37       0.99         1.91
  Stage IV         44 (43.6)      40 (39.6)    17 (16.8)   0.440                                                            128 (63.4)   74 (36.6)    0.566                                                            1.11       0.78         1.58
  \>12 months      51 (34.2)      72 (48.3)    26 (17.4)   0.130                                                            174 (58.4)   124 (41.6)   **0.048**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.37**   **1.00**     **1.86**
  ≤12 months       53 (36.0)      73 (49.7)    21 (14.3)   0.350                                                            179 (60.9)   115 (39.1)   0.191                                                            1.23       0.90         1.69
  **rs1573954**    **TT**         **TC**       **CC**      ***P***[a](#tfn12-medscimonit-25-3750){ref-type="table-fn"}      **T**        **C**        ***P***[b](#tfn13-medscimonit-25-3750){ref-type="table-fn"}      **OR**     **95% CI**   
  Controls         48 (24.6)      105 (53.9)   42 (21.5)                                                                    201 (51.5)   189 (48.5)                                                                                            
  Unilateral       13 (18.8)      31 (44.9)    25 (36.2)   **0.046**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   57 (41.3)    81 (58.7)    **0.039**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.51**   **1.02**     **2.24**
  Bilateral        45 (19.7)      116 (50.9)   67 (29.4)   0.082                                                            206 (45.2)   250 (54.8)   0.065                                                            1.29       0.98         1.69
  Stage II         12 (16.2)      31 (41.9)    31 (41.9)   **0.005**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   55 (37.2)    93 (62.8)    **0.003**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.80**   **1.22**     **2.65**
  Stage III        18 (15.0)      69 (57.5)    33 (27.5)   **0.010**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   105 (43.8)   135 (56.3)   0.058                                                            1.37       0.99         1.89
  Stage IV         28 (27.2)      47 (45.6)    28 (27.2)   0.440                                                            103 (50.0)   103 (50.0)   0.721                                                            1.06       0.76         1.49
  \>12 months      30 (19.9)      76 (50.3)    45 (29.8)   0.130                                                            136 (45.0)   166 (55.0)   0.090                                                            1.30       0.96         1.75
  ≤12 months       28 (19.2)      71 (48.6)    47 (32.2)   0.084                                                            127 (43.5)   165 (56.5)   **0.037**[\*](#tfn11-medscimonit-25-3750){ref-type="table-fn"}   **1.38**   **1.02**     **1.87**

*P*\<0.05 indicates statistical significance.

*P* values were calculated by Wald test adjusted for age;

*P* was calculated by Pearson chi-squared test.

Bold values indicate a significant difference.

###### 

The haplotype frequencies of *MMP20* polymorphisms and their association with alcohol-induced ONFH risk.

      Haplotype   Freq   OR[b](#tfn16-medscimonit-25-3750){ref-type="table-fn"} (95% CI)   *P*[b](#tfn16-medscimonit-25-3750){ref-type="table-fn"}                                               
  --- ----------- ------ ----------------------------------------------------------------- --------------------------------------------------------- --- --- --- --- ------- ------------------- ------------------------------------------------------------
  1   T           A      T                                                                 C                                                         G   C   T   G   0.377   1                   --
  2   C           G      G                                                                 T                                                         T   C   C   A   0.278   1.63 (1.15--2.30)   0.006[\*](#tfn15-medscimonit-25-3750){ref-type="table-fn"}
  3   C           A      G                                                                 C                                                         T   C   C   G   0.088   1.68 (1.00--2.82)   0.051
  4   C           A      G                                                                 T                                                         T   C   C   A   0.074   0.89 (0.51--1.53)   0.670
  5   C           A      G                                                                 C                                                         T   T   C   G   0.062   1.14 (0.63--2.07)   0.670
  6   C           A      T                                                                 C                                                         G   C   T   G   0.055   0.79 (0.44--1.43)   0.440

*P*\<0.05 indicates statistical significance.

Adjusted by age.

Bold values indicate a significant difference.
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